Table 1.
The baseline characteristics of the included studies
| FNB/LB | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Studies | SD | Cases | Mean age | Female | BMI | Anesthesia | FNB | Dose of LB | CPM | Follow‐up |
| Broome (2014) | Non‐RCT | 100/100 | — | — | — | SA | CFNB | — | Oral morphine | 3 days |
| Cien (2015) | Non‐RCT | 65/57 | 62.6/61.9 | 41/36 | 34.5/34.6 | GA | SFNB | 266 mg LB | Hydrocodone equivalents | 1 month |
| Emerson JR (2016) | Non‐RCT | 36/36 | 64.2/66.9 | 22/26 | 34.7/32.5 | GA | CFNB | 266 mg LB | Morphine equivalents | 5 days |
| Horn (2015) | Non‐RCT | 16/16 | 63.8/66.1 | 14/14 | — | SA | SFNB | 266 mg LB | Oral, intravenous, and PCA | 2 days |
| Kirkness (2016) | Non‐RCT | 134/134 | 67.6/67.1 | 77/74 | 32.2/32.7 | SA/GA | CFNB | 266 mg LB | Morphine equivalents | 3 days |
| Marino (2018) | RCT | 32/33 | 64.2/62.3 | 17/15 | 33.1/32.6 | SA | CFNB | 266 mg LB | Oral, intravenous, and PCA | 3 days |
| Sporer 2016 | Non‐RCT | 325/272 | 65/63.4 | 202/168 | 33.0/33.2 | SA | SFNB | 266 mg LB | IV hydromorphone, tramadol,tapentadol, morphine andoxycodone acetaminophen | 3 days |
| Surdam (2015) | RCT | 40/40 | 68.4/64.9 | 21/23 | — | SA | SFNB | 266 mg LB | IV morphine, Dilaudid, fentanyl and oxycodone | 4 weeks |
| Talmo (2018) | RCT | 161/151 | 62.32/62.01 | 73/81 | 30.06/30.71 | — | SFNB | 266 mg LB | Oral hydromorphone equivalents | 1 year |
| Torres (2017) | Non‐RCT | 23/23 | 66.0/64.4 | 14/14 | — | SA | CFNB |
20 cc of LB in 40 cc in 0.9% NS |
Morphine equivalents | 3 weeks |
| Yu (2016) | Non‐RCT | 583/531 | 66/65 | 385/356 | 32/32 | SA/GA | SFNB |
20 cc of LB in 40 cc in 0.9%NS |
Oral narcotics, intravenousmorphine | 3 days |
BMI, body mass index; CFNB, continuous femoral nerve block; CPM, concomitant pain management; FNB, femoral nerve block; GA, general anesthesia; LB, liposomal bupivacaine; RCT, randomized controlled study; SA, spine anesthesia; SD, study design; SFNB, single femoral nerve block.